Association of genetic polymorphisms of CXCL12/SDF1 gene and its receptor, CXCR4, to the susceptibility and prognosis of non-small cell lung cancer

Lee, Yao-Ling; Kuo, Wu‐Hsien; Lin, Chiao‐Wen; Chen, Wei; Chen, Shuo-Chueh; Shih, Chuen-Ming

doi:10.1016/j.lungcan.2010.12.011

Cited by 28 publications

(24 citation statements)

References 34 publications

(39 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…All studies indicated that the distribution of genotypes in the controls was consistent with HWE except for only 1 study. [16] The sample size ranged between 2831 and 5967. Two genotyping methods were utilized in the studies, including TaqMan and polymerase chain reaction restriction fragment length polymorphism.…”

Section: Resultsmentioning

confidence: 99%

“…[13,14] Several molecular epidemiological studies showed that CXCR4 was highly mutated and had a pro-oncogenic role in cancers, including renal cell carcinoma, [15] nonsmall cell lung cancer, [16] oral cancer, [17] hepatocellular carcinoma, [18] acute myeloid leukemia, [19] and breast cancer. [20] However, other studies indicated that there was no significant association between rs2228014 polymorphism and cancer risk, such as endometrial carcinoma, [21] bladder cancer, [22] chronic lymphocytic leukemia, [23] breast cancer, [24] and prostate cancer.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

CXC motif chemokine receptor 4 gene polymorphism and cancer risk

Zhang

et al. 2016

Medicine

View full text Add to dashboard Cite

Background:Previous epidemiological studies have reported the relationship between CXC motif chemokine receptor 4 (CXCR4) synonymous polymorphism (rs2228014), and risk of cancer, but the results remained conflicting and controversial. Therefore, this study was devised to evaluate the genetic effects of the rs2228014 polymorphism on cancer risk in a large meta-analysis.Methods:The computer-based databases (EMBASE, Web of Science, and PubMed) were searched for all relevant studies evaluating rs2228014 and susceptibility to cancer. In the analysis, pooled odds ratios (ORs) with its corresponding 95% confidence intervals (CIs) were calculated in 5 genetic models to assess the genetic risk. Egger regression and Begg funnel plots test were conducted to appraise the publication bias.Results:Data on rs2228014 polymorphism and overall cancer risk were available for 3684 cancer patients and 5114 healthy controls participating in 11 studies. Overall, a significantly increased risk of cancer was associated with rs2228014 polymorphism in homozygote model (OR = 2.01, 95% CI: 1.22–3.33) and in recessive model (OR = 1.97, 95% CI: 1.23–3.16). When stratified by ethnicity, the results were positive only in Asian populations (heterozygote model: OR = 1.36, 95% CI: 1.13–1.65; homozygote model: OR = 2.43, 95% CI: 1.21–4.91; dominant model: OR = 1.47, 95% CI: 1.13–1.90; recessive model: OR = 2.25, 95% CI: 1.13–4.48; and allele model: OR = 1.48, 95% CI: 1.10–1.99). Besides, in the subgroup analysis by source of control, the result was significant only in population-based control (homozygote model: OR = 2.39, 95% CI: 1.06–5.40; recessive model: pooled OR = 2.24, 95% CI: 1.02–4.96).Conclusion:In general, our results first indicated that the rs2228014 polymorphism in CXCR4 gene is correlated with an increased risk of cancer, especially among Asian ethnicity. Large, well-designed epidemiological studies are required to verify the current findings.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

CXC motif chemokine receptor 4 gene polymorphism and cancer risk

Zhang

et al. 2016

Medicine

View full text Add to dashboard Cite

show abstract

“…These researches involved 36 case-control studies, 4932 cancer cases and 7917 healthy controls, and assessed the association between CXCL12 G801A polymorphism and cancer risk [10,[12][13][14] . Among the 29 eligible papers, 7 of them enrolled Asian subjects [10, [28][29][30][31][32][33] and 22 examined Caucasian ones [12][13][14][34][35][36][37][38][39][40][41][42][43][44][45][46][47][48][49][50][51][52] (table 1). In all studies, cancer cases were diagnosed histologically or pathologically and blood samples were used for genotyping.…”

Section: Characteristics Of Eligible Studiesmentioning

confidence: 99%

CXCL12 G801A polymorphism and cancer risk: An updated meta-analysis

Meng

Heerah

et al. 2015

J. Huazhong Univ. Sci. Technol. [Med. Sci.]

View full text Add to dashboard Cite

Many studies have reported the relationship between CXCL12 G801A polymorphism and cancer risk, with conflicting results. In this study, we tried to clarify the possibility that this polymorphism may increase cancer risk by conducting an updated meta-analysis. PubMed and EMbase were searched for case-control studies regarding the association of the gene polymorphism and cancer risk. Data were extracted and odds ratios (ORs) with 95% confidence intervals (95% CIs) were used to assess the strength of the association. Heterogeneity among articles and publication bias was also assessed. Significantly increased risk for cancer was found (A vs. G: OR=1.26, 95% CI=1.13-1.40, P<0.01; AA+AG vs. GG: OR=1.33, 95% CI=1.16-1.52, P<0.01). In subgroup analysis, statistically elevated cancer risk was found in both Asian and Caucasian populations (for Asian, AA+AG vs. GG: OR=1.74, 95% CI=1.22-2.47, P<0.01; for Caucasian, AA+AG vs. GG: OR=1.24, 95% CI=1.09-1.42, P<0.01). Our result indicated that CXCL12 G801A polymorphism is a risk factor for cancer. To validate the finding, further large-size case-control studies are warranted.

show abstract

“…The 5-year disease-free survival rate for patients with high CXCR7 levels (63.2%) was significantly lower than that for patients with low CXCR7 levels (84.8%) (P = 0.033) [78]. Lee et al recently confirmed the involvement of CXCR12 and CXCR4 in NSCLC, showing that patients carrying a homologous AA genotype at CXCL12-3 or a homologous TT genotype at CXCR4-138 tended to have more advanced disease and poorer prognoses than the other patients [79].…”

Section: Lung Cancermentioning

confidence: 99%